Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.43 |
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.40 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.38 |
| ▸ | NPY4R | P50391 | 7/20 | 0.38 |
| ▸ | NPY1R | P25929 | 5/20 | 0.38 |
| ▸ | NPY2R | P49146 | 5/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.38 |
| ▸ | GNPAT | O15228 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30662552 | 0.98 | NOD1 (0.42) | NOD1FNTAFNTBPGGT1BC3AR1 | |
| SCHEMBL29880860 | 0.93 | GNPAT (0.41) | NOD1C3AR1PTGS1GSTK1NPY4R | |
| SCHEMBL17748346 | 0.93 | NOD1 (0.43) | NOD1FNTAFNTBPGGT1BC3AR1 | |
| SCHEMBL17748347 | 0.93 | NOD1 (0.43) | NOD1FNTAFNTBPGGT1BC3AR1 | |
| SCHEMBL27632326 | 0.91 | NOD1 (0.51) | NOD1FNTAFNTBPGGT1BC3AR1 | |
| SCHEMBL27632323 | 0.91 | NOD1 (0.51) | NOD1FNTAFNTBPGGT1BC3AR1 | |
| SCHEMBL29942412 | 0.91 | NPY4R (0.41) | NOD1PTGS1GSTK1NPY4RNPY1R | |
| SCHEMBL31099287 | 0.91 | NOD1 (0.45) | NOD1FNTAFNTBPGGT1BNPY4R | |
| SCHEMBL2068782 | 0.91 | GNPAT (0.40) | NOD1FNTAFNTBPGGT1BNPY4R | |
| SCHEMBL9440021 | 0.90 | NOD1 (0.43) | NOD1FNTAFNTBPGGT1BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536265-A2 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Jenius Pharma, LLC (US) | 2025-04-16 | — | — | EP | claimed |
| US-20240384007-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2024-11-21 | — | — | US | claimed |
| EP-4389216-A2 | PEPTIDE COMPOSITIONS AND THERAPEUTIC USES | Allegro Pharmaceuticals, LLC (US) | 2024-06-26 | — | — | EP | claimed |
| US-11999802-B2 | Compositions and methods for selective protein degradation | NOVARTIS AG (CH) | 2024-06-04 | — | — | US | claimed |
| US-20240132542-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC | 2024-04-25 | — | — | US | claimed |
| WO-2023239716-A2 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC (US) | 2023-12-14 | — | — | WO | claimed |
| EP-4219721-A2 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | Novartis AG (CH) | 2023-08-02 | — | — | EP | claimed |
| US-20230174933-A1 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | NOVARTIS AG (CH) | 2023-06-08 | — | — | US | claimed |
| US-20230071283-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | Payne, Aimee S. (US) | 2023-03-09 | — | — | US | claimed |
| EP-3443096-B1 | COMPOSITIONS AND METHODS FOR SELECTIVE EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS | NOVARTIS AG (CH) | 2023-03-01 | — | — | EP | claimed |
| EP-4110377-A2 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | Novartis AG (CH) | 2023-01-04 | — | — | EP | claimed |
| CN-115397460-A | Methods of making cells expressing chimeric antigen receptors | 诺华股份有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-115340996-A | Co-expression method of multi-subunit protein by using specific enzyme cutting site | 态创生物科技(广州)有限公司 | 2022-11-15 | — | — | CN | claimed |
| CN-111494642-B | Self-assembly material for in-situ construction of artificial extracellular matrix and preparation method and application thereof | 国家纳米科学中心 | 2022-10-14 | — | — | CN | claimed |
| US-20220307053-A1 | REGULATABLE EXPRESSION SYSTEMS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-09-29 | — | — | US | claimed |
| US-20220175667-A1 | Extracellular Matrices, Uses Thereof, and Methods of Making Extracellular Matrices | THE JOHNS HOPKINS UNIVERSITY | 2022-06-09 | — | — | US | claimed |
| EP-4004213-A1 | REGULATABLE EXPRESSION SYSTEMS | Novartis AG (CH) | 2022-06-01 | — | — | EP | claimed |
| CN-114174514-A | Adjustable expression system | 诺华股份有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-110627912-B | Bionic fiber network antibody self-assembly material and preparation method and application thereof | 国家纳米科学中心 | 2022-03-08 | — | — | CN | claimed |
| US-12612638-B2 | Fusion constructs to express biopharmaceutical polypeptides in cyanobacteria | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250382328-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | JENIUS PHARMA LLC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12454549-B2 | Treatments for diseases and disorders that involve oxidative stress | JENIUS PHARMA, LLC (US) | 2025-10-28 | — | — | US | disclosed |
| CN-120137971-A | Adjustable expression system | 诺华股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250129342-A1 | ALPHAVIRUS REPLICON PARTICLE | VLP THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4536265-A2 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Jenius Pharma, LLC (US) | 2025-04-16 | — | — | EP | disclosed |
| US-12227770-B2 | Alphavirus replicon particle | VLP THERAPEUTICS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20240384007-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2024-11-21 | — | — | US | disclosed |
| CN-118388659-A | Method for rapidly preparing multiple MHC-antigen peptide tetramers and application thereof | 苏州系统医学研究所 | 2024-07-26 | — | — | CN | disclosed |
| EP-4389216-A2 | PEPTIDE COMPOSITIONS AND THERAPEUTIC USES | Allegro Pharmaceuticals, LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11999802-B2 | Compositions and methods for selective protein degradation | NOVARTIS AG (CH) | 2024-06-04 | — | — | US | disclosed |
| WO-2023239716-A2 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-111019927-B | Recombinant plasmid for expressing TEV protein, recombinant engineering bacterium and method for preparing and purifying TEV protein | 重庆艾力彼生物科技有限公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-4219721-A2 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| US-20230174933-A1 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | NOVARTIS AG (CH) | 2023-06-08 | — | — | US | disclosed |
| CN-110938151-B | Fusion protein for expressing parathyroid hormone PTH, recombinant plasmid and recombinant engineering bacteria | 重庆艾力彼生物科技有限公司 | 2023-03-17 | — | — | CN | disclosed |
| US-20230071283-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | Payne, Aimee S. (US) | 2023-03-09 | — | — | US | disclosed |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3443096-B1 | COMPOSITIONS AND METHODS FOR SELECTIVE EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS | NOVARTIS AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| US-20230056486-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | ENCLEAR THERAPIES INC (US) | 2023-02-23 | — | — | US | disclosed |
| EP-4110377-A2 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | Novartis AG (CH) | 2023-01-04 | — | — | EP | disclosed |
| CN-115397460-A | Methods of making cells expressing chimeric antigen receptors | 诺华股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220372499-A1 | FUSION CONSTRUCTS TO EXPRESS BIOPHARMACEUTICAL POLYPEPTIDES IN CYANOBACTERIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-11-24 | — | — | US | disclosed |
| CN-115340996-A | Co-expression method of multi-subunit protein by using specific enzyme cutting site | 态创生物科技(广州)有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-111494642-B | Self-assembly material for in-situ construction of artificial extracellular matrix and preparation method and application thereof | 国家纳米科学中心 | 2022-10-14 | — | — | CN | disclosed |
| US-20220307053-A1 | REGULATABLE EXPRESSION SYSTEMS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-09-29 | — | — | US | disclosed |
| US-11419921-B2 | Methods of treating neurological disorders | ENCLEAR THERAPIES, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220251152-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2022-08-11 | — | — | US | disclosed |
| EP-4028529-A1 | FUSION CONSTRUCTS TO EXPRESS BIOPHARMACEUTICAL POLYPEPTIDES IN CYANOBACTERIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20220175667-A1 | Extracellular Matrices, Uses Thereof, and Methods of Making Extracellular Matrices | THE JOHNS HOPKINS UNIVERSITY | 2022-06-09 | — | — | US | disclosed |
| EP-4004213-A1 | REGULATABLE EXPRESSION SYSTEMS | Novartis AG (CH) | 2022-06-01 | — | — | EP | disclosed |
| CN-114174514-A | Adjustable expression system | 诺华股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-110627912-B | Bionic fiber network antibody self-assembly material and preparation method and application thereof | 国家纳米科学中心 | 2022-03-08 | — | — | CN | disclosed |
| CN-110627912-B | Bionic fiber network antibody self-assembly material and preparation method and application thereof | 国家纳米科学中心 | 2022-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230071283-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | BCL6, BCL3, BCL6B | NOD1 3517/4885FNTA 2520/4885FNTB 1785/4885 |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | NOD1 3250/4885FNTA 2305/4885FNTB 318/4885 |
| US-20240132542-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | GPX4, GPX1, TXNRD2 | NOD1 3637/4885FNTA 3181/4885FNTB 3703/4885 |
| US-12612638-B2 | Fusion constructs to express biopharmaceutical polypeptides in cyanobacteria | CPB2, IRF2BP2, SPPL2B | NOD1 3240/4885FNTA 789/4885FNTB 53/4885 |
| US-20240384007-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | CRBN, RPS27A, COPB1 | NOD1 3242/4885FNTA 2885/4885FNTB 2489/4885 |
| US-20220175667-A1 | Extracellular Matrices, Uses Thereof, and Methods of Making Extracellular Matrices | EPCAM, CD44, MATR3 | NOD1 3974/4885FNTA 1053/4885FNTB 2575/4885 |
| US-12454549-B2 | Treatments for diseases and disorders that involve oxidative stress | GPX4, GPX1, TXNRD2 | NOD1 3637/4885FNTA 3181/4885FNTB 3703/4885 |
| US-20250382328-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | GPX4, GPX1, TXNRD2 | NOD1 3637/4885FNTA 3181/4885FNTB 3703/4885 |
| US-11999802-B2 | Compositions and methods for selective protein degradation | CRBN, RPS27A, COPB1 | NOD1 3242/4885FNTA 2885/4885FNTB 2489/4885 |
| US-20230174933-A1 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | HAVCR2, MICA, CD74 | NOD1 2550/4885FNTA 1677/4885FNTB 1513/4885 |
| US-20220251152-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | RPS27A, PSMG3, PREP | NOD1 3072/4885FNTA 893/4885FNTB 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.